Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

by Per E. Lønning
Published 2012-05-01

Constitutional Mosaic Epimutations – a hidden cause of cancer?

by Per E. Lønning, Hans P. Eikesdal, Inger M. Løes, Stian Knappskog
Published 2019-03-01

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells

by Johanna Huun, Liv B. Gansmo, Bård Mannsåker, Gjertrud Titlestad Iversen, Jan Inge Øvrebø, Per E. Lønning, Stian Knappskog
Published 2017-04-01

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

by Johanna Huun, Liv B. Gansmo, Bård Mannsåker, Gjertrud T. Iversen, Jan Sommerfelt-Pettersen, Jan Inge Øvrebø, Per E. Lønning, Stian Knappskog
Published 2017-10-01

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.

by Andliena Tahiri, Kathrine Røe, Anne H Ree, Rik de Wijn, Karianne Risberg, Christian Busch, Per E Lønning, Vessela Kristensen, Jürgen Geisler
Published 2013-01-01

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

by Elin Borgen, Maria C. Rypdal, Maria Soledad Sosa, Anne Renolen, Ellen Schlichting, Per E. Lønning, Marit Synnestvedt, Julio A. Aguirre-Ghiso, Bjørn Naume
Published 2018-10-01

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.

by Cornelia Schuster, Hans P Eikesdal, Hanne Puntervoll, Jürgen Geisler, Stephanie Geisler, Daniel Heinrich, Anders Molven, Per E Lønning, Lars A Akslen, Oddbjørn Straume
Published 2012-01-01

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.

by Stian Knappskog, Liv B Gansmo, Pål Romundstad, Merete Bjørnslett, Jone Trovik, Jan Sommerfelt-Pettersen, Erik Løkkevik, Norwegian Breast Cancer Group trial NBCG VI, Rob A E M Tollenaar, Caroline Seynaeve, Peter Devilee, Helga B Salvesen, Anne Dørum, Kristian Hveem, Lars Vatten, Per E Lønning
Published 2012-01-01

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

by Gro V. Røsland, Sissel E. Dyrstad, Deusdedit Tusubira, Reham Helwa, Tuan Zea Tan, Maria L. Lotsberg, Ina K. N. Pettersen, Anna Berg, Charlotte Kindt, Fredrik Hoel, Kirstine Jacobsen, Ari J. Arason, Agnete S. T. Engelsen, Henrik J. Ditzel, Per E. Lønning, Camilla Krakstad, Jean P. Thiery, James B. Lorens, Stian Knappskog, Karl J. Tronstad
Published 2019-06-01